Mary Ann Karam

727 total citations
28 papers, 534 citations indexed

About

Mary Ann Karam is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Mary Ann Karam has authored 28 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 17 papers in Molecular Biology and 16 papers in Oncology. Recurrent topics in Mary Ann Karam's work include Multiple Myeloma Research and Treatments (22 papers), Protein Degradation and Inhibitors (9 papers) and Cancer Treatment and Pharmacology (8 papers). Mary Ann Karam is often cited by papers focused on Multiple Myeloma Research and Treatments (22 papers), Protein Degradation and Inhibitors (9 papers) and Cancer Treatment and Pharmacology (8 papers). Mary Ann Karam collaborates with scholars based in United States, Egypt and Uganda. Mary Ann Karam's co-authors include Mohamad A. Hussein, Rachid Baz, Gordan Srkalović, Beth Faiman, Janice Reed, Steven Andrèsen, Megan Kelly, Jerome B. Zeldis, Kandice Kottke‐Marchant and Liang Li and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Mayo Clinic Proceedings.

In The Last Decade

Mary Ann Karam

27 papers receiving 525 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary Ann Karam United States 12 360 265 235 113 63 28 534
Mirjana Mitrović Serbia 11 250 0.7× 150 0.6× 54 0.2× 68 0.6× 43 0.7× 54 436
Dragica Tomin Serbia 12 353 1.0× 165 0.6× 64 0.3× 114 1.0× 17 0.3× 36 434
A. Franke Germany 11 135 0.4× 58 0.2× 107 0.5× 117 1.0× 72 1.1× 28 362
Ebru Koca Türkiye 13 167 0.5× 57 0.2× 108 0.5× 71 0.6× 14 0.2× 35 337
Marijana Virijević Serbia 10 204 0.6× 112 0.4× 47 0.2× 62 0.5× 26 0.4× 47 300
Shinya� Fujita Japan 11 191 0.5× 54 0.2× 79 0.3× 61 0.5× 140 2.2× 53 462
Aline Schmidt France 11 320 0.9× 62 0.2× 139 0.6× 153 1.4× 8 0.1× 44 526
Yeu‐Chin Chen Taiwan 11 136 0.4× 54 0.2× 51 0.2× 46 0.4× 12 0.2× 55 313
M. Cole‐Sinclair Australia 8 187 0.5× 72 0.3× 90 0.4× 172 1.5× 6 0.1× 13 339
Harris Naina United States 11 68 0.2× 58 0.2× 122 0.5× 29 0.3× 13 0.2× 60 356

Countries citing papers authored by Mary Ann Karam

Since Specialization
Citations

This map shows the geographic impact of Mary Ann Karam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Ann Karam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Ann Karam more than expected).

Fields of papers citing papers by Mary Ann Karam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Ann Karam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Ann Karam. The network helps show where Mary Ann Karam may publish in the future.

Co-authorship network of co-authors of Mary Ann Karam

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Ann Karam. A scholar is included among the top collaborators of Mary Ann Karam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Ann Karam. Mary Ann Karam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Covut, Fahrettin, Christy Samaras, Faiz Anwer, et al.. (2019). External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients. Blood. 134(Supplement_1). 3148–3148. 1 indexed citations
2.
Lee, Sarah S., Bhumika Patel, Mary Ann Karam, et al.. (2018). Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis. Blood. 132(Supplement 1). 2009–2009. 6 indexed citations
3.
Khouri, Jack, Bicky Thapa, Frederic J. Reu, et al.. (2018). Daratumumab proves safe and highly effective in AL amyloidosis. British Journal of Haematology. 185(2). 342–344. 39 indexed citations
4.
Reu, Frederic J., Dale Grabowski, Reda Z. Mahfouz, et al.. (2015). A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.. Journal of Clinical Oncology. 33(15_suppl). 8584–8584. 2 indexed citations
5.
Narkhede, Mayur, Jason Valent, Chad Cummings, et al.. (2014). Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy. Blood. 124(21). 2620–2620. 2 indexed citations
6.
7.
Choueiri, Toni K., Rachid Baz, Mohamad Khasawneh, et al.. (2007). An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. British Journal of Urology. 101(6). 712–715. 19 indexed citations
8.
Baz, Rachid, Suzanne Fanning, Lori Kunkel, et al.. (2007). Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma. Leukemia & lymphoma. 48(12). 2338–2344. 11 indexed citations
9.
Hussein, Mohamad A., Rachid Baz, Gordan Srkalović, et al.. (2006). Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma. Mayo Clinic Proceedings. 81(7). 889–895. 84 indexed citations
10.
Abou-Jawde, Rony M., Janice Reed, Megan Kelly, et al.. (2006). Efficacy and Safety Results with the Combination Therapy of Arsenic Trioxide, Dexamethasone, and Ascorbic Acid in Multiple Myeloma Patients: A Phase 2 Trial. Medical Oncology. 23(2). 263–272. 33 indexed citations
11.
Baz, Rachid, Megan Kelly, Janice Reed, et al.. (2006). Phase II study of dexamethasone, ascorbic acid, thalidomide and arsenic trioxide (DATA) in high risk previously untreated (PU) and relapsed/refractory (RR) multiple myeloma (MM). Journal of Clinical Oncology. 24(18_suppl). 17535–17535. 3 indexed citations
12.
Abou-Jawde, Rony M., Rachid Baz, Esteban Walker, et al.. (2006). The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma.. PubMed. 91(10). 1410–3. 24 indexed citations
13.
Baz, Rachid, Liang Li, Kandice Kottke‐Marchant, et al.. (2005). The Role of Aspirin in the Prevention of Thrombotic Complications of Thalidomide and Anthracycline-Based Chemotherapy for Multiple Myeloma. Mayo Clinic Proceedings. 80(12). 1568–1574. 168 indexed citations
14.
15.
16.
17.
Hussein, M. A., et al.. (2003). Skeletal Trauma Preceding the Development of Plasma Cell Dyscrasia: Eight Case Reports and Review of the Literature. Medical Oncology. 20(4). 349–354. 8 indexed citations
18.
Hussein, M. A., et al.. (2003). Etanercept Therapy in Patients with Advanced Primary Amyloidosis. Medical Oncology. 20(3). 283–290. 15 indexed citations
19.
Srkalović, Gordan, et al.. (2002). Use of Melphalan, Thalidomide, and Dexamethasone in Treatment of Refractory and Relapsed Multiple Myeloma. Medical Oncology. 19(4). 219–226. 38 indexed citations
20.
Katabira, Elly, Nelson K. Sewankambo, Roy D. Mugerwa, et al.. (1998). Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial.. Sexually Transmitted Infections. 74(4). 265–270. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mirjana Mitrović Breakdown of academic impact, for papers by Dragica Tomin Breakdown of academic impact, for papers by A. Franke Breakdown of academic impact, for papers by Ebru Koca Breakdown of academic impact, for papers by Marijana Virijević Breakdown of academic impact, for papers by Shinya� Fujita Breakdown of academic impact, for papers by Aline Schmidt Breakdown of academic impact, for papers by Yeu‐Chin Chen Breakdown of academic impact, for papers by M. Cole‐Sinclair Breakdown of academic impact, for papers by Harris Naina
Rankless by CCL
2026